Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative PainPRNewsWire • 09/28/20
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative PainPRNewsWire • 09/08/20
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate UpdatesPRNewsWire • 08/05/20
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/27/20
Implied Volatility Surging for Heron Therapeutics (HRTX) Stock OptionsZacks Investment Research • 06/29/20
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative PainPRNewsWire • 06/29/20
Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/21/20
Heron Therapeutics, Inc. (HRTX) Shares March Higher, Can It Continue?Zacks Investment Research • 11/25/19
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/30/19